PP405: New Hair Loss Drug for Transplant Patients

PP405 is an oral CRTH2 receptor antagonist that blocks the prostaglandin D2 pathway responsible for follicle suppression and miniaturisation in androgenetic alopecia. Minoxidil and finasteride leave this pathway entirely unaddressed, which is why a significant proportion of patients on existing treatment still experience progressive loss. Phase 2 trial data published in 2024 showed statistically significant improvements in hair count and thickness at 24 weeks, placing PP405 on a regulatory pathway that makes it a near-term clinical reality.

According to Dr Harikiran Chekuri, one of India’s pioneering plastic surgeon, “PP405 is worth paying attention to because it targets a pathway existing approved treatments don’t touch, and for patients where prostaglandin D2 signalling is the primary driver of their hair loss, that distinction changes what the treatment conversation actually looks like.“

PP405 works through a mechanism with no currently approved equivalent, which is what separates it from every other oral hair loss drug on the market. The receptor it targets has been identified in hair loss research for over a decade with no pharmaceutical answer until now.

• CRTH2 blockade: Blocking the CRTH2 receptor stops prostaglandin D2 from firing the follicle-suppressing signal that drives miniaturisation, and no approved drug currently addresses this receptor at all.
• Anagen prolongation: Follicles pushed prematurely into telogen by PGD2 activity stay in active growth longer once that signal is removed, and that cycle shift is where the density improvements in trial data actually originate.
• DHT independence: The androgen pathway is not involved here, which matters for patients where PGD2 elevation rather than DHT sensitivity is what’s actually driving their loss.
• Oral delivery: No topical compliance issues, no scalp irritation, no missed applications. The patient takes a pill and the mechanism runs consistently, which is a practical clinical advantage over topical alternatives.
• Trial evidence: 24-week Phase 2 data showed statistically significant hair count and thickness improvement versus placebo, and Phase 3 is now in progress with regulatory submission in view.

PP405 doesn’t replace existing treatments but adds a real clinical option where current approved mechanisms have run out of road. For patients in Hyderabad, Redefine Hair Transplant and Plastic Surgery Center builds every protocol around what’s actually driving that individual’s hair loss before any medical or surgical plan is established.

Surgery moves follicles. It does nothing for ongoing miniaturisation in the hair that wasn’t transplanted, and that gap is exactly where PP405 becomes clinically relevant for patients who have had or are planning a transplant.

• Pre-surgical stabilisation: Slowing miniaturisation in the recipient zone before surgery through PGD2 blockade improves the scalp environment grafts are going into, and that matters for long-term density outcomes.
• Post-surgical protection: Native non-transplanted hair keeps thinning after surgery through whatever mechanism was driving loss before, and for PGD2-active patients finasteride and minoxidil don’t cover that specific pathway.
• Combination potential: Running PP405 alongside existing medical therapy means the androgen pathway and the prostaglandin pathway are both addressed simultaneously, which is the multi-mechanism gap that leaves single-drug patients plateauing.
• Patient selection: Elevated PGD2 activity isn’t universal, and PP405 belongs specifically in protocols where standard post-surgical medical therapy hasn’t controlled ongoing loss in non-transplanted areas.
• Scalp environment: PGD2-driven follicular inflammation affects graft survival and long-term density, and reducing it before and after surgery creates measurably better conditions for the transplanted hair to establish and hold.

Transplant surgery and medical therapy produce better long-term outcomes together than either does alone, and PP405 adds a genuinely new mechanism to that combination for the right patient. Read about regenerative hair transplant to understand how biological protocols and surgical planning work together to protect long-term hair restoration outcomes.